Market Overview:
The global nuclear receptor ROR gamma market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of chronic diseases, rising awareness about the benefits of nuclear receptor ROR gamma drugs, and increasing investments by pharmaceutical companies in research and development (R&D) activities for new drug molecules. However, patent expirations of key marketed drugs may restrain the growth of this market during the forecast period. Based on type, the global nuclear receptor ROR gamma market is segmented into BBI-6000, GRC-39815Action, R&D Progress, GSK-2981278 IMU-366 INV-17 Others. Based on application, it is segmented into chronic obstructive pulmonary disease (COPD), asthma axial spondyloarthritis (axSpA), breast cancer others).
Product Definition:
A nuclear receptor ror gamma is a type of receptor that is found in the nucleus of cells. It helps to regulate gene expression by binding to specific DNA sequences. This receptor is important for development and regulation of the immune system.
BBI-6000:
It was developed by PerkinElmer Inc. and is under clinical investigation in the U.S., Europe, Japan, and China for treatment of multiple myeloma and prostate cancer.
GRC-39815Action:
GRC-39815 is a nuclear receptor ROR gamma that is selective for the activation of G proteins and has no activity at CB1 or CB2 receptors. It was discovered by screening a collection of compounds libraries against the Nuclear Receptor 1 (NUC1) gene sequence, which encodes for the human cannabinoid receptor.
Application Insights:
The chronic obstructive pulmonary disease (COPD) segment dominated the global nuclear receptor ROR gamma market in 2017. COPD is a major public health concern, with over 30 million people suffering from the condition worldwide. According to estimates by Global Burden of Disease Study, an annual incidence of around 17 million cases has been reported globally and it is expected that more than 50 million people would be affected by 2030 if corrective measures are not taken.
Rising awareness about risk factors such as smoking and air pollution among individuals susceptible to develop COPD will drive demand for new therapeutic options for this disease. This factor also supports growth of the COPD segment due to high prevalence in developing countries like India, China Japan etc., which have a growing population prone to diseases owing to unhealthy lifestyles including heavy drinking and smoking habits during early stages of life-course.
Regional Analysis:
North America dominated the global market in terms of revenue share in 2017. This can be attributed to the presence of a large number of nuclear receptor ROR gamma developers and manufacturers coupled with high healthcare expenditure, technological advancements, and favorable reimbursement policies & regulatory reforms. In addition, increasing government funding for R&D activities is also expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to factors such as economic development and rising disposable income leading to an increase in consumer awareness regarding early diagnosis followed by treatment options for various diseases including chronic obstructive pulmonary disease (COPD), asthma, axial spondyloarthritis (ASA), breast cancer among others.
Growth Factors:
- Increasing prevalence of chronic diseases such as cancer, diabetes, and obesity is expected to drive the demand for nuclear receptor ROR gamma therapeutics over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth owing to increasing incidence of age-related disorders such as cancer and Alzheimer’s disease.
- Rising awareness about benefits of nuclear receptor ROR gamma drugs is projected to propel the market growth in near future.
- Technological advancements in drug development are likely to provide lucrative opportunities for market players over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Nuclear Receptor ROR Gamma Market Research Report
By Type
BBI-6000, GRC-39815Action, R&D Progress, GSK-2981278, IMU-366, INV-17, Others
By Application
Chronic Obstructive Pulmonary Disease, Asthma, Axial Spondyloarthritis, Breast Cancer, Others
By Companies
Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies, Beijing Hanmi Pharmaceutical, Biogen Inc, AbbVie Inc, Eurofins Advinus, Brickell Biotech Inc, Pfizer Inc, Phenex Pharmaceuticals AG, Genfit SA, Bristol-Myers Squibb Company, Celgene Corp, Eli Lilly, Glenmark Pharmaceuticals, Lead Pharma Holding BV
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
129
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Nuclear Receptor ROR Gamma Market Report Segments:
The global Nuclear Receptor ROR Gamma market is segmented on the basis of:
Types
BBI-6000, GRC-39815Action, R&D Progress, GSK-2981278, IMU-366, INV-17, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Obstructive Pulmonary Disease, Asthma, Axial Spondyloarthritis, Breast Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genfit SA
- GlaxoSmithKline Plc
- Aurigene Discovery Technologies
- Beijing Hanmi Pharmaceutical
- Biogen Inc
- AbbVie Inc
- Eurofins Advinus
- Brickell Biotech Inc
- Pfizer Inc
- Phenex Pharmaceuticals AG
- Genfit SA
- Bristol-Myers Squibb Company
- Celgene Corp
- Eli Lilly
- Glenmark Pharmaceuticals
- Lead Pharma Holding BV
Highlights of The Nuclear Receptor ROR Gamma Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BBI-6000
- GRC-39815Action
- R&D Progress
- GSK-2981278
- IMU-366
- INV-17
- Others
- By Application:
- Chronic Obstructive Pulmonary Disease
- Asthma
- Axial Spondyloarthritis
- Breast Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Nuclear Receptor ROR Gamma Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
ROR Gamma is a nuclear receptor that regulates the activity of other genes.
Some of the key players operating in the nuclear receptor ror gamma market are Genfit SA, GlaxoSmithKline Plc, Aurigene Discovery Technologies, Beijing Hanmi Pharmaceutical, Biogen Inc, AbbVie Inc, Eurofins Advinus, Brickell Biotech Inc, Pfizer Inc, Phenex Pharmaceuticals AG, Genfit SA, Bristol-Myers Squibb Company, Celgene Corp, Eli Lilly, Glenmark Pharmaceuticals, Lead Pharma Holding BV.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Nuclear Receptor ROR Gamma Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Nuclear Receptor ROR Gamma Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Nuclear Receptor ROR Gamma Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Nuclear Receptor ROR Gamma Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Nuclear Receptor ROR Gamma Market Size & Forecast, 2020-2028
4.5.1 Nuclear Receptor ROR Gamma Market Size and Y-o-Y Growth
4.5.2 Nuclear Receptor ROR Gamma Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 BBI-6000
5.2.2 GRC-39815Action
5.2.3 R&D Progress
5.2.4 GSK-2981278
5.2.5 IMU-366
5.2.6 INV-17
5.2.7 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Chronic Obstructive Pulmonary Disease
6.2.2 Asthma
6.2.3 Axial Spondyloarthritis
6.2.4 Breast Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Nuclear Receptor ROR Gamma Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Nuclear Receptor ROR Gamma Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 BBI-6000
9.6.2 GRC-39815Action
9.6.3 R&D Progress
9.6.4 GSK-2981278
9.6.5 IMU-366
9.6.6 INV-17
9.6.7 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Chronic Obstructive Pulmonary Disease
9.10.2 Asthma
9.10.3 Axial Spondyloarthritis
9.10.4 Breast Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 BBI-6000
10.6.2 GRC-39815Action
10.6.3 R&D Progress
10.6.4 GSK-2981278
10.6.5 IMU-366
10.6.6 INV-17
10.6.7 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Chronic Obstructive Pulmonary Disease
10.10.2 Asthma
10.10.3 Axial Spondyloarthritis
10.10.4 Breast Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 BBI-6000
11.6.2 GRC-39815Action
11.6.3 R&D Progress
11.6.4 GSK-2981278
11.6.5 IMU-366
11.6.6 INV-17
11.6.7 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Chronic Obstructive Pulmonary Disease
11.10.2 Asthma
11.10.3 Axial Spondyloarthritis
11.10.4 Breast Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 BBI-6000
12.6.2 GRC-39815Action
12.6.3 R&D Progress
12.6.4 GSK-2981278
12.6.5 IMU-366
12.6.6 INV-17
12.6.7 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Chronic Obstructive Pulmonary Disease
12.10.2 Asthma
12.10.3 Axial Spondyloarthritis
12.10.4 Breast Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 BBI-6000
13.6.2 GRC-39815Action
13.6.3 R&D Progress
13.6.4 GSK-2981278
13.6.5 IMU-366
13.6.6 INV-17
13.6.7 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Chronic Obstructive Pulmonary Disease
13.10.2 Asthma
13.10.3 Axial Spondyloarthritis
13.10.4 Breast Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Nuclear Receptor ROR Gamma Market: Competitive Dashboard
14.2 Global Nuclear Receptor ROR Gamma Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Genfit SA
14.3.2 GlaxoSmithKline Plc
14.3.3 Aurigene Discovery Technologies
14.3.4 Beijing Hanmi Pharmaceutical
14.3.5 Biogen Inc
14.3.6 AbbVie Inc
14.3.7 Eurofins Advinus
14.3.8 Brickell Biotech Inc
14.3.9 Pfizer Inc
14.3.10 Phenex Pharmaceuticals AG
14.3.11 Genfit SA
14.3.12 Bristol-Myers Squibb Company
14.3.13 Celgene Corp
14.3.14 Eli Lilly
14.3.15 Glenmark Pharmaceuticals
14.3.16 Lead Pharma Holding BV
